Revance Therapeutics Inc (NASDAQ:RVNC) – Equities researchers at Cantor Fitzgerald raised their FY2017 earnings per share estimates for shares of Revance Therapeutics in a research report issued on Thursday. Cantor Fitzgerald analyst L. Chen now forecasts that the biopharmaceutical company will post earnings of ($3.85) per share for the year, up from their prior estimate of ($3.88). Cantor Fitzgerald currently has a “Buy” rating and a $50.00 price target on the stock. Cantor Fitzgerald also issued estimates for Revance Therapeutics’ FY2018 earnings at ($3.17) EPS.
A number of other research analysts have also weighed in on RVNC. Guggenheim started coverage on Revance Therapeutics in a report on Tuesday, December 5th. They set a “buy” rating and a $42.00 price objective on the stock. Mizuho upped their price objective on Revance Therapeutics from $37.00 to $54.00 and gave the stock a “buy” rating in a report on Wednesday, December 6th. SunTrust Banks upped their price objective on Revance Therapeutics to $53.00 and gave the stock a “buy” rating in a report on Friday, December 8th. Zacks Investment Research downgraded Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Barclays started coverage on Revance Therapeutics in a research note on Monday, November 27th. They issued an “overweight” rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $42.11.
Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.06). The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. Revance Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.64) EPS.
Several hedge funds and other institutional investors have recently made changes to their positions in RVNC. SG Americas Securities LLC bought a new stake in shares of Revance Therapeutics in the 3rd quarter worth approximately $144,000. Bank of America Corp DE increased its position in Revance Therapeutics by 29.5% in the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 1,651 shares during the period. Legal & General Group Plc increased its position in Revance Therapeutics by 8.1% in the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 438 shares during the period. Trexquant Investment LP acquired a new stake in Revance Therapeutics in the 2nd quarter valued at approximately $231,000. Finally, Voya Investment Management LLC acquired a new stake in Revance Therapeutics in the 2nd quarter valued at approximately $274,000. 88.58% of the stock is currently owned by institutional investors and hedge funds.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $23.58, for a total transaction of $179,208.00. Following the transaction, the chief executive officer now owns 148,450 shares of the company’s stock, valued at approximately $3,500,451. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Mark J. Foley bought 20,000 shares of Revance Therapeutics stock in a transaction on Tuesday, November 7th. The shares were purchased at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now owns 6,000 shares in the company, valued at $161,760. The disclosure for this purchase can be found here. Insiders sold 44,026 shares of company stock valued at $1,135,234 in the last three months. 18.86% of the stock is currently owned by company insiders.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.